Formosa Pharmaceuticals Investors
Financials
Consolidated Financial Statements
- 2025 Q1 Consolidated Financial Statements
- 2024 Q4 Consolidated Financial Statements
- 2024 Q3 Consolidated Financial Statements
- 2024 Q2 Consolidated Financial Statements
- 2024 Q1 Consolidated Financial Statements
- 2023 Q4 Consolidated Financial Statements
- 2023 Q3 Consolidated Financial Statements
- 2023 Q2 Consolidated Financial Statements
- 2022 Q4 Consolidated Financial Statements
- 2022 Q2 Consolidated Financial Statements
- 2021 Q4 Consolidated Financial Statements
- 2021Q2 Consolidated Financial Statements
- 2020 Consolidated Financial Statements
- 2019 Consolidated Financial Statements
Parent Company Only Financial Statements
News Highlight
Harrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Nanosuspension) 0.05% from Formosa Pharmaceuticals
2025-06-09
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals NASHVILLE, Tenn. and Taipei, Taiwan, June 9, 2025 – Harrow (Nasdaq: HROW), a leading North
